PTC Therapeutics executive VP and CLO Mark Elliott Boulding reports sale of $174,013.31 in common shares
PTCT•PTC Therapeutics executive Mark Elliott Boulding sold 2,812 common shares on Nov. 16, 2026, and exercised options for 2,812 shares at $25.69 each. He directly owned 105,272 shares and held 14,064 options after the transactions.
1. Share transactions
Boulding sold 2,812 common shares on Nov. 16, 2026: 1,315 at $61.39, 1,288 at $62.22 and 209 at $62.90. On the same date, he exercised stock options for 2,812 shares at $25.69 per share. After the transactions, he directly owned 105,272 common shares and held 14,064 stock options.




